Plus Therapeutics Inc. (PSTV)
0.74
-0.05 (-5.98%)
At close: Apr 11, 2025, 1:20 PM
Company Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases.
Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment.
The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019.
Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Plus Therapeutics Inc.
| Country | United States |
| IPO Date | Jul 11, 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Dr. Marc H. Hedrick M.B.A., M.D. |
Contact Details
Address: 4200 Marathon Boulevard Austin, Texas United States | |
| Website | https://www.plustherapeutics.com |
Stock Details
| Ticker Symbol | PSTV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001095981 |
| CUSIP Number | 72941H400 |
| ISIN Number | US72941H5090 |
| Employer ID | 33-0827593 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marc H. Hedrick M.B.A., M.D. | President, Chief Executive Officer & Director |
| Andrew J. Sims CPA | Vice President of Finance & Chief Financial Officer |
| Desiree Smith | Corporate Controller |
| Dr. Michael Stanley Rosol Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | DEF 14A | Filing |
| Apr 04, 2025 | S-3 | Filing |
| Apr 01, 2025 | PRER14A | Filing |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | RW | Filing |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 18, 2025 | SCHEDULE 13G | Filing |
| Mar 14, 2025 | PRE 14A | Filing |
| Mar 10, 2025 | 424B3 | Filing |
| Mar 10, 2025 | 8-K | Current Report |